Transaction #22827 · Form 4 · 0001193125-26-424421
Beam Therapeutics Inc. · Exercise / conversion · Common Stock
Beam Therapeutics Inc. · Transacted October 16, 2026 · Filed October 16, 2026
What does this filing report?
An SEC Form 4 filing for Beam Therapeutics Inc. records an exercise / conversion involving Common Stock on October 16, 2026. The reported quantity was 25,000. The filing date is October 16, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Beam Therapeutics Inc.
- Company CIK
- 0001745999
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 25,000
- Reported price
- 1.03
- Reference value
- 25,750
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 1,072,205
- Ownership description
- Not reported
- SEC acceptance time
- Oct 16, 2026, 8:09 PM EDT
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Evans John M. ↗
CEO · Director
CIK 0001786304
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2026.
- F2
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.23 to $23.84, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.66 to $24.56, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4
- On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.